June 20, 2018
Policy Prescriptions: The firepower of the EU Pharmaceutical Lobby and Implications for Public Health
This report exposes the excessive lobbying influence of the pharmaceutical industry on EU decision-making. Big pharma enjoys semi-systematic privileged access to decision-making in Brussels, facilitated by its vast lobby expenditure, complex web of actors, extensive meetings with policy-makers, and participation in advisory groups.
Sign up for free news and updates from Children’s Health Defense. CHD focuses on legal strategies to defend the health of our children and obtain justice for those injured. We can't do it without your support.